3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in evidence-based management of UTUC.

          Related collections

          Author and article information

          Journal
          Eur Urol
          European urology
          Elsevier BV
          1873-7560
          0302-2838
          Jul 2023
          : 84
          : 1
          Affiliations
          [1 ] GRC 5 Predictive Onco-Uro, Sorbonne University, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France. Electronic address: morgan.roupret@aphp.fr.
          [2 ] GRC 5 Predictive Onco-Uro, Sorbonne University, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France.
          [3 ] Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK; University of Manchester, Manchester, UK.
          [4 ] Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia; Department of Pathology, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria.
          [5 ] Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia; Department of Pathology, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria; Department of Pathology, Sorbonne University, AP-HP, Hôpital Tenon, Paris.
          [6 ] Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
          [7 ] Patient advocate, Bladder Cancer Norway, Norway.
          [8 ] Department of Translational Medicine, Lund University, Malmö, Sweden; Department of Urology, Skåne University Hospital, Malmö, Sweden.
          [9 ] Department of Urology, Edinburgh Bladder Cancer Surgery, Western General Hospital, Edinburgh, UK.
          [10 ] Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK.
          [11 ] Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France.
          [12 ] Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
          [13 ] Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
          [14 ] Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
          [15 ] Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
          [16 ] Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris, Paris, France.
          [17 ] Department of Urology, Université de Paris, AP-HP, Saint Louis Hospital, Paris, France.
          Article
          S0302-2838(23)02652-0
          10.1016/j.eururo.2023.03.013
          36967359
          f3b9b591-1bcc-4013-a200-791bee31f15b
          History

          Chemotherapy,Genetic screening,Immunotherapy,Management,Prognostic factors,Renal pelvis,Surgery,Ureter,Urothelial carcinoma,(Neo)adjuvant therapy

          Comments

          Comment on this article